)
Samir Ounzain, PhD
CEO and Co-founder
HAYA Therapeutics
Samir Ounzain, PhD, is Co-Founder and CEO of HAYA Therapeutics, a Swiss-US biotechnology company pioneering a new class of precision RNA medicines targeting the regulatory genome. With more than 20 years of experience exploring the “dark matter” of human biology, he is advancing long non-coding RNA therapeutics designed to reprogram disease-driving cell states at their root.
Under his leadership, HAYA has evolved from foundational discovery into a platform-driven company advancing first-in-class programs in cardio-renal and chronic diseases. He has secured top-tier venture backing and led strategic partnerships, including a major collaboration with Eli Lilly and Company focused on novel regulatory RNA targets in obesity and related metabolic disease.
Samir’s vision is to make medicine programmable, preventive, and precise by unlocking the regulatory layer of the genome that governs cellular identity. He believes many chronic conditions, from fibrosis to cardiometabolic and inflammatory disorders, are sustained by maladaptive cell states that can be reset through targeted RNA-guided interventions.
He has been recognized among The Power List 2025 in Advanced Medicine, named one of Pharmaceutical Executive’s Emerging Pharma Leaders, and honored with the Andreas and Thomas Struengmann Award for visionary scientific entrepreneurship.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}